¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"common pathway of coagulation"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • common hepatic duct
    ¿Â°£°ü, ÃѰ£°ü
  • common iliac artery
    ¿Â¾ûµ¢µ¿¸Æ, ÃÑÀå°ñµ¿¸Æ
  • common iliac lymph node
    ¿Â¾ûµ¢¸²ÇÁÀý, ÃÑÀå°ñ¸²ÇÁÀý
  • common integument
    ¿ÜÇÇ
  • common interosseous artery
    ¿Â»À»çÀ̵¿¸Æ, ÃѰñ°£µ¿¸Æ
  • common nevus
    º¸Åë¸ð¹Ý
  • common opsonin
    Á¤»ó¿É¼Ò´Ñ
  • common palmar digital artery
    ¿Â¹Ù´ÚÂʼհ¡¶ôµ¿¸Æ, ÃÑÀåÃøÁöµ¿¸Æ
  • common palmar digital nerve
    ¿Â¹Ù´ÚÂʼհ¡¶ô½Å°æ, ÃѼöÀåÃøÁö½Å°æ
  • common peroneal nerve
    ¿ÂÁ¾¾Æ¸®½Å°æ, ÃѺñ°ñ½Å°æ
  • common plantar digital artery
    ¿Â¹Ù´ÚÂʹ߰¡¶ôµ¿¸Æ, ÃÑ̫̿Áöµ¿¸Æ
  • common plantar digital nerve
    ¿Â¹Ù´ÚÂʹ߰¡¶ô½Å°æ, ÃÑÁ·ÀúÃøÁö½Å°æ
  • common ratio
    °øºñ
  • common synovial sheath
    ¿ÂÀ±È°Áý
  • common tendinous ring
    ¿ÂÈûÁÙ°í¸®
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • common factor
    °øÅëÀÎÀÚ
  • common integument
    ¿ÜÇÇ
  • common nevus
    º¸Åë¸ð¹Ý
  • common opsonin
    (¢¡normal opsonin) Á¤»ó¿É¼Ò´Ñ
  • common ratio
    °øºñ
  • common reaction
    Á¤»ó¹ÝÀÀ
  • common tendon
    °øÅëÈûÁÙ, °øÅë°Ç
  • common vehicle
    °øÅë¸Å°³Ã¼
  • common ventricle
    °øÅë½É½Ç, ´Ü½É½Ç
  • common wart
    (¢¡verruca vulgaris) º¸Åë»ç¸¶±Í
  • common bile duct
    ¿Â¾µ°³°ü, ÃÑ´ã°ü
  • common dorsal mesentery
    ¿ÂµîÂÊâÀÚ°£¸·
  • common duct exploration
    ¿Â¾µ°³°üŽ»ö¼ú, ÃÑ´ã°üŽ»ö¼ú
  • common duct stone
    ¿Â¾µ°³°üµ¹, ÃÑ´ã°ü°á¼®
  • common hepatic duct
    ¿Â°£°ü
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • accessory pathway
    ºÎÀüµµ·Î.
  • acetate pathway
    ¾Æ¼¼Å×ÀÌÆ® ´ë»ç°æ·Î(¡­ÓÛÞóÌèÖØ).
  • acoustic pathway
    û°¢·Î
  • alternative pathway
    ±³´ë°æ·Î
  • alternative pathway
    º°µµ°æ·Î, ´ëü°æ·Î
  • biosynthetic pathway
    »ýÇÕ¼º°úÁ¤<°æ·Î>(¡­<ÌèÖØ>).
  • biosynthetic pathway
    »ýÇÕ¼º°æ·Î(¡­ÌèÖØ).
  • classic pathway
    ÀüÇüÀû °æ·Î
  • classical pathway
    °íÀü°æ·Î, °íÀüÀû°æ·Î (º¸Ã¼¹ÝÀÀÀÇ)
  • complement system, alternative pathway
    ´ëü°æ·Î(ÓÛôðÌèÖØ)
  • complement system, classic pathway
    ÀüÇüÀû °æ·Î(îðúþîÜÌèÖØ)
  • corticastriatal pathway
    ÇÇÁú¼±Á¶Ã¼°æ·Î(ù«òõàÊðÉô÷ÌèÖØ)
  • cyclooxygenase pathway
    »çÀÌŬ·Î¿Á½Ã°Ô³ªÁ¦ ȸ·Î(¡­üÞÖØ)
  • direct oxidative pathway
    Á÷Á¢»êÈ­°æ·Î.
  • dopaminergic pathway
    µµÆÄ¹Î °æ·Î
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • phosphoketolase pathway
    Æ÷½ºÆ÷ÄÉÅç·¹À̽º °æ·Î(ÌèÖØ)
  • properdin pathway
    ÇÁ·ÎÆä¸£µò °æ·Î(ÌèÖØ)
  • reversible metabolic pathway
    °¡¿ª ´ë»ç°æ·Î(ÓÛÞóÌèÖØ)
  • salvage pathway
    ÀçÀÌ¿ë °æ·Î(î¢××éÄÌèÖØ)
  • shikimic acid pathway
    ½¬Å´»ê(ß«) °æ·Î(ÌèÖØ)
  • short patch pathway
    ´ÜÆí °æ·Î(Ó­ø¸ÌèÖØ)
  • succinate pathway
    ¼÷½Å»ê(ß«) °æ·Î(ÌèÖØ)
  • tiered metabolic pathway
    ÃþÃþ´ë»ç °æ·Î (öµöµÓÛÞóÌèÖØ)
  • Warburg-Dickens pathway
    ¹Ù¸£ºÎ¸£Å©-µðŲ½º °æ·Î(ÌèÖØ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
ICF immunodeficiency-centromeric instability-facial anomalies [syndrome]; indirect centrifugal flotation...
IVBC intravascular blood coagulation
IVC inferior vena cava; inspiratory vital capacity; integrated vector control; intravascular coagulation...
LACI lipoprotein-associated coagulation inhibitor
LIC left internal carotid [artery]; limiting isorrheic concentration; local intravascular coagulation
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
rTFPI Recombinant tissue factor pathway inhibitor
TFPI TF pathway inhibitor
TFPI Tissue Factor Pathway Inhibitor
TFPI-2 Tissue factor pathway inhibitor-2
APC alternative pathway of complement
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • conscious pathway
    ÀǽÄÀûÀÎ Àüµµ·Î
    ½Äº°¼º Ã˰¢ ¹× ¾Ð°¢ÀÇ Àüµµ·Î¿Í ÀÏÄ¡.
  • descending pathway
    ÇÏÇà °æ·Î
  • dorsal column pathway
    ¹è ôÁÖ °æ·Î
    Ã˰¢ÀÇ A
  • efferent neural pathway
    ¿ø½É¼º ½Å°æ·Î
    ÁßÃ߽Űæ°è·ÎºÎÅÍ Àü´ÞµÇ¾î ³ª°¡´Â ½Å°æ ÀÓÆÞ½º.
  • humoral pathway
    ü¾× Åë·Î
  • intrinsic pathway
    ³»ºÎ °æ·Î, ³»Àμº °æ·Î
  • medial pathway
    ³»Ãø °æ·Î
  • meridian pathway
    °æ¶ô, °æ·Î
    µ¿¾ç ÀÇÇп¡¼­ ¹°¸® ¿ä¹ý, ƯÈ÷ ħ±¸ Ä¡·áÀÇ À̷Рü°è·Î¼­ Áß¿ä½ÃµÇ´Â °æÇ÷
  • metabolic pathway
    ´ë»ç °æ·Î
  • neural pathway
    ½Å°æ °æ·Î, ½Å°æ Åë·Î
    ÀÓÆÞ½º°¡ Àü´ÞµÇ´Â ½Å°æ ±¸Á¶¹°.
  • orbiting pathway
    ±Ëµµ
  • paleothalamic pathway
    °í½Ã»ó Àü´Þ·Î
  • paramedian pathway
    Á¤Áß¹æ °æ·Î
  • pathway
    °æ·Î, Àüµµ·Î
    Àüµµ·Î¶ó°í ÇÏ´Â °ÍÀº ³ú ¶Ç´Â ô¼ö¿¡ À־ÀÇ ÁßÃß¿Í ½Åü ¸»Ãʸ¦ ¿¬°áÇÏ´Â Åõ»ç ½Å°æ·Î¸¦ ¸»ÇÏ´Â °ÍÀ¸·Î Åõ»ç ½Å°æ·Î´Â ½Ä¹° ½Å°æ°è¿¡ ¼ÓÇÏ´Â °Í°ú µ¿¹° ½Å°æ°è¿¡ ¼ÓÇÏ´Â °ÍÀ¸·Î ´ëº°ÇÒ ¼ö ÀÖ´Ù. ±×ÀÇ ¾î´À °Í¿¡µµ »óÇ༺
  • pentose hosphate pathway

    pentose nucleic acid (ÆæÅ佺 ÇÙ»ê

CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
DNA repair pathway The sequence of steps in the repair of DNA. Each step is governed by an enzyme.
(12 Dec 1998)
drug development pathway The various procedures and studies that must be undertaken to satisfy Food and Drug Administration requirements for drug approval and marketing.
(14 Nov 1997)
intrinsic pathway <haematology> Initiation of blood clotting as a result of factors released from damaged tissue, as opposed to contact with a foreign surface (the intrinsic pathway).
Tissue thromboplastin (Factor III) in conjunction with Factor VII proconvertin) will activate Factor X that, once activated, converts prothrombin to thrombin.
(27 Jun 1999)
Embden-Meyerhof-Parnas pathway A pathway that degrades glucose to pyruvate, the six-carbon stage converts glucose to fructose-1,6-bisphosphate, and the three-carbon stage produces ATP while changing glyceraldehyde-3-phosphate to pyruvate.
Compare: Entner-Doudoroff pathway.
(09 Oct 1997)
Embden-Meyerhof pathway The main pathway for anerobic degradation of carbohydrate. Starch or glycogen is hydrolysed to glucose 1 phosphate and then through a series of intermediates, yielding two ATP molecules per glucose and producing either pyruvate which feeds into the tricarboxylic acid cycle) or lactate.
(18 Nov 1997)
Entner-Douderoff pathway A degradative pathway for carbohydrates in certain microorganisms (e.g., Pseudomonas sp.) that lack hexokinase, phosphofructokinase, and glyceraldehyde-3-phosphate dehydrogenase.
(05 Mar 2000)
Entner-Doudoroff pathway <biochemistry> A pathway that converts glucose to pyruvate and glyceraldehyde-3 phosphate by producing 6-phosphogluconate and then dehydrating it.
(09 Oct 1997)
extrinsic pathway <haematology> Initiation of blood clotting as a result of factors released from damaged tissue, as opposed to contact with a foreign surface (the intrinsic pathway).
Tissue thromboplastin (Factor III) in conjunction with Factor VII proconvertin) will activate Factor X that, once activated, converts prothrombin to thrombin.
(27 Jun 1999)
4-aminobutyrate pathway The pathway that ultimately converts 4-aminobutyrate to succinate; succinate is then converted to alpha-ketoglutarate, via the tricarboxylic acid cycle, which is then acted upon by glutamate dehydrogenase; glutamate is then decarboxylated to reform 4-aminobutyrate; an important pathway for those cells which make this neuroactive molecule.
Synonym: GABA pathway.
(05 Mar 2000)
lysogenic pathway <virology> The method by which a virus becomes a dormant, passive part of its host bacterium's genome (a lysogenic virus), choosing to insert its DNA into the host's and postponing completion of its lytic cycle, at which time it destroys the host and spreads its progeny to infect other bacterial cells (enters the lytic pathway).
(09 Oct 1997)
lytic pathway The steps in the method that a virus takes to complete a lytic cycle, including the production and assembly of progeny viruses with host cell machinery and the destruction of the host cell by rupturing its plasma membrane (lysis), releasing the progeny viruses in the process.
(09 Oct 1997)
carotid artery, common The two principal arteries supplying the structures of the head and neck. They ascend in the neck, one on each side, and at the level of the upper border of the thyroid cartilage, each divides into two branches, the external (carotid artery, external) and internal (carotid artery, internal) carotid arteries.
(12 Dec 1998)
migraine, common Migraine without aura. The most frequent type, accounting for about 80-85% of migraines. See migraine.
(12 Dec 1998)
cold, common A viral upper respiratory tract infection. A contagious illness caused by a number of different types of viruses. Because of the great number of viruses that can cause a cold, the body never builds up resistance (immune) against all of them. For this reason, colds are a frequent and recurring problem. In fact, preschool children average 9 colds a year; those in kindergarten, 12 colds a year; and adolescents and adults, 7 colds per year. Going out into the cold weather has no effect on the spread of a cold. Antibiotics do not help the common cold.
(12 Dec 1998)
common acute lymphoblastic leukaemia <haematology, oncology> A sub-type of acute lymphoblastic leukaemia affecting cells early in the B lymphocyte lineage which accounts for about 80% of all acute lymphoblastic leukaemia.
Origin: Gr. Haima = blood
(13 Nov 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • common trust fund
    °øµ¿ÅõÀÚ½ÅŹÀÚ±Ý
  • common year
    Æò³â
  • common-garden
    =COMMON-OR-GARDEN
  • common-law
    °ü½À¹ýÀÇ;°ü½À¹ý»óÀÇ
  • common-law marriage
    °ü½À¹ý È¥ÀÎ;³»¿¬ °ü°è
  • common-law wife
    ³»¿¬ÀÇ Ã³
  • common-or-garden
    º¸ÅëÀÇ;ÈçÇÑ;ÀÏ»óÀûÀÎ
  • common-or-garden-variety
    =COMMON-OR-GARDEN
  • european common market
    À¯·´°øµ¿½ÃÀå
  • greatest common divisor(divisor)
    ÃÖ´ë °ø¾à¼ö
  • lowest common denominator
    ÃÖ¼Ò °ø¹è¼ö
  • right of common
    °øÀ¯±Ç;ÀÔȸ±Ç
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á